Mainstay Medical Applies for Approval to Market ReActiv8® in Australia
Dublin, Ireland: 12 January 2017 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable neurostimulation system to treat disabling Chronic Low Back Pain ("CLBP"), announces that it has applied for ReActiv8 to be admitted to the Australian Register of Therapeutic Goods (ARTG) which would allow for commercialization in Australia.
Mainstay's ARTG application includes the results of the ReActiv8-A Clinical Trial, which showed clinically important, statistically significant, and lasting improvement in pain, disability, and quality of life for people with Chronic Low Back Pain and limited treatment options.
More info on Mainstay Medical's website.
Next > Avantium in the 2017 Global Cleantech 100
Previous > Avantium acquires Liquid Light